

Broad pipeline targeting early to late-stage cancer treatment

	Asset	Indication	Rights	Preclinical	Phase 1	Phase 2	Phase 3	Upcoming Catalyst
Oncology								
Off-the-shelf	VB10.16	HPV16+ cervical cancer	1				C-02, C-04	Initiate trial (Q2 2024)
		HPV16+ head and neck cancer	2				C-03	Dose level recommendation (H2 2024)
		HPV16+ locally advanced cervical cancer	3				C-05	Protocol in development
	Regeneron programs	Undisclosed	4					Selection of lead candidate
	NYK011	Colorectal: pre-cancerous polyps to cancer	4					Update (H2 2024)
Individualized	VB10.NEO	Melanoma, lung, bladder, renal, head and neck cancer; locally advanced and metastatic tumors	5				N-01	
		Locally advanced and metastatic tumors	5				N-02	
Infectious Disease								
Regeneron programs		Undisclosed	4					
Autoimmune								
Internal		Undisclosed	4					Update (H1 2024)

1. Wholly-owned by Nykode. Potentially registrational. Roche supplies atezolizumab; 2. Wholly-owned by Nykode. Merck (MSD) supplies pembrolizumab; 3. Wholly-owned Nykode. 4. Collaboration with Regeneron; 5. Genentech has an exclusive license to VB10.NEO.